anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
Patients suffering from serious arthritis may receive the artificial joint replacement surgery. Comparing to the articulation of articular cartilage, the artificial joint undergo a boundary lubrication in which a thin layer of synovial fluid molecules is formed between the artificial joint materials. Therefore a larger wear rate is observed in the artificial joint system. Researchers have devoted themselves to modifying the artificial joint materials in order to reduce the wear phenomena. We first propose that modification the lubrication by adding effective lubricating molecules may help to reduce the wear of artificial joint. However, there still lacks fundamentally understanding of the artificial joint lubrication mechanism under synovial fluid. Hence, we plan to investigate the boundary lubrication mechanism of synovial molecules, such as albumin, globulin, hyaluronic acid, and lipid in the first year. We would like to obtain the adsorption behaviors of the single molecules as well as multiple molecules on the surfaces of artificial joint materials by experiments. Molecular dynamics simulation will also be performed to gain the knowledge of adsorption energy and possible conformation change of the molecules. In the second year, the tribological heat and mechanical effects on the synovial molecules will be studied. The analysis platform will be established to perform the composition and properties measurement of the synovial molecules. In the third year, we will further discuss the effect of the synovial molecules transformation on the surrounding cells and tissues. Their influences on the tribological and biochemical behaviors will be investigated.
The novel positively charged pro-drugs of mustards and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be synthesized from mustards and related compounds by reaction with suitable alcohols, thiols or amines and coupling agents, such as: n, N '-dicyclohexylcarbodiimide, N' -diisopropylcarbodiimide, O-benzotriazol-N, N '-tetramethyluronium tetrafluoroborate (TBTU), O-benzotriazol-N, N' -tetramethyluronium Hexafluorophosphate (HBTU), benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (BOP), and the like. The positively charged amino groups of these pro-drugs not only greatly increase the solubility of the drugs in water, but also bond to the negative charge on the phosphate head group of membranes and push the pro-drug molecules into the cytosol. The results of the experiments indicate that the pro-drugs permeate human skin 100 times faster than do mustards and related compounds. In plasma, more than 90% of the pro-drugs can return to the parent drug structure within a few minutes. These prodrugs can be used to treat any mustards and related compounds-treatable conditions in humans or animals. In therapy, these prodrugs can be administered transdermally, avoiding most of the side effects of mustards and related compounds. Controlled transdermal administration systems of these pro-drugs allow for the stabilization of mustards and related compounds in blood at optimal therapeutic concentrations, increase efficacy and reduce the side effects of mustards and related compounds. Another great benefit of transdermal administration of these prodrugs is that administration is more convenient, particularly for children.
A longitudinal incision of 3cm was made along the scrotal raphe using a scalpel. Surgical dissection proceeded layer by layer. The testis was separated from the surrounding dartos and luxated outside the scrotal sac. A longitudinal incision was made in the tunica vaginalis to allow complete exposure of the tunica albuginea. Two Vicryl 2-0 traction sutures were placed 0.5 cm cranially and caudally to the testicular equatorial line, which was subsequently incised with a scalpel for 3/4 of the testicular circumference. In M-TESE, through the operating microscope, a direct examination of the testicular parenchyma was performed under magnification (20-25x). Multiple testicular specimens were excised. The same procedure is performed on the contralateral side, where instead of the operating microscope, the surgeon uses surgical loupes for magnification (3.5 - 5x).
Autism Spectrum Disorders (ASD) are characterized by difficulties in language, social communication, and repetitive and restricted behaviors. ASD affects as many as 1 in 90-150 children. Sleep issues/insomnia is very common in children with ASD (50-80%). Insomnia has a negative impact on both the developmental and behavioral function of the child and the quality of life for the family. Causes of insomnia in children with ASD are multifactorial and can be difficult to treat effectively. Low iron stores, as manifest by low serum ferritin levels, is also common in children with ASD. Both insomnia and low iron stores are associated with Restless Legs Syndrome (RLS) and Periodic Limb Movement of Sleep (PLMS). Children with ASD often have difficulty communicating symptoms or tolerating Polysomnography (Sleep Study). This makes establishing a diagnosis of RLS or PLMS very difficult in children with ASD. Because polysomnography is not well tolerated in children with ASD and cannot measure sleep over time in a natural environment, improvements in sleep with treatment with iron will be measured by standard actigraphy (a watch that measures movements during sleep) and sleep diaries. The investigators also propose to evaluate periodic limb movement index (PLMI) as a predictor of response to iron treatment for insomnia in children with ASD, as measured by the PAM-RL, an actigraph designed to measure PLMS. The investigators will collect secondary data regarding attention and behavior over the course of the study to monitor improvement in daytime functioning in both groups. Many clinicians will empirically treat children with ASD, insomnia and low ferritin levels (\< 50ng/ml) with iron. This is based on data from a previous open label trial demonstrating subjective improvement in restless sleep in children with ASD with low/low normal ferritin levels who were treated with iron. In order to evaluate the efficacy of such treatment, The investigators propose a randomized placebo-controlled trial of oral elemental iron for treatment of insomnia in children with ASD and ferritin levels that are low but above the laboratory cut off for deficiency. This study will evaluate the effectiveness of treatment of insomnia with oral ferrous sulfate (iron) at a dose of 3mg/kg divided twice per day for 3 months compared to placebo.
Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
OBJECTIVE: Sepsis-associated liver injury is responsible for the high morbidity and mortality rates seen with septic shock. Activation of the renin-angiotensin-aldosterone system (RAAS) is an essential counteractive mechanism during the hypotensive phase of sepsis; however, excessive activation is associated with exaggerated pro-oxidant and inflammatory response, which aggravates organ damage. This study aimed to evaluate the effect of RAAS inhibition on sepsis-induced liver damage.
MATERIALS AND METHODS: The cecal ligation and puncture (CLP) model was employed as a model of sepsis. Rats were divided into five groups: sham-operated, vehicle-treated septic rats, septic rats treated with ramipril in a dose of 10 mg/kg, septic rats treated with losartan in a dose of 20 mg/kg, and finally septic rats treated with spironolactone in a dose of 25 mg/kg. Rats received the treatment one hour after induction. Twenty-four hours later, rats were euthanized, and serum samples and liver tissue were collected to evaluate liver function and hepatic oxidative, anti-oxidative, inflammatory, and apoptotic markers. The microscopic integrity of the hepatic tissue was also assessed.
RESULTS: The results of our study showed that all the treatments used ameliorated sepsis-induced liver injury. This was reflected by improved liver function parameters and histopathological appearance of liver tissue. Treatment with ramipril, losartan, or spironolactone reduced tissue malondialdehyde (MDA), nitric oxide, activated caspase-3, and TNF-α. Moreover, these drugs increased hepatic reduced-glutathione (GSH) levels, superoxide dismutase (SOD) activity, and proliferating cell nuclear antigen (PCNA) expression.
CONCLUSIONS: Administration of ramipril, losartan, or spironolactone after CLP produced a hepatoprotective effect in rats, possibly by reducing oxidative stress, inflammation, and apoptosis.
Dry solid pharmaceutical compositions comprising at least one non-toxic orally-acceptable fat at least 70 per cent of the particles of which are less than 20 microns in size in the presence of at least one non-toxic orally-acceptable emulsifying agent are prepared by freeze drying or spray drying the corresponding non-toxic orally-acceptable fat emulsions.  These emulsions used as starting materials may be prepared from liquid p  paraffin, coconut oil, corn oil, arachis oil, butter oil, olive oil or cod liver oil.  The emulsifying agent may be gelatine, acacia, tragacanth, methyl cellulose, sodium carboxy-methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, alginates, egg lecithin, agar, sorbitol, sorbitan mono-oleate, polyoxyethylene sorbitan tri-oleate or the condensation product of ethylene oxide with 8-10 molecular proportions of octylcresol. As non-toxic orally-acceptable excipients there may be added sodium chloride, sodium citrate, potassium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, dextrose, dextran, casein hydrolysate, and mixtures of amino-acids or enzyme digested protein optionally with the addition of vitamins.  The dry solid composition obtained by drying the fat emulsion can be reconstituted to form a nontoxic orally-acceptable emulsion in which the small size of the fat particles in the original emulsion is retained and which is stable by the addition of an aqueous non-toxic orally-acceptable medium such as water or milk.  It is preferred that at least 70 per cent of the fat particles present are not greater than 3 microns in size.  The preferred solid composition contains by weight 50-90 per cent fat, 3-25 per cent emulsifying agent, 8-30 per cent carbohydrate.  A particularly useful composition is one containing about 55 per cent by weight of fat.
PURPOSE:The titled composition, containing an alkyl ester salt of a mono N- long chain acyl basic amino acid, a straight chain saturated alcohol, a sorbitan ester of a fatty acid, etc., capable of improving the luster and brushability of hair, and having improved dispersion stability. CONSTITUTION:A hair cosmetic composition containing 0.1-5wt% alkyl ester salt of a mono N-long chain acyl basic amino acid, e.g. lauroyllysine methyl ester hydrochloride, 0.7-5wt% 14-22C straight chain saturated alcohol, 0.1- 2wt% sorbitan ester of a fatty acid, e.g. sorbitan monooleate, 0.1-2wt% polyglycerol ester of a fatty acid, e.g. diglycerol monostearate, and 0.5-10wt% polyhydric alcohol or an alkylene oxide adduct derivative thereof, e.g. propylene glycol. The above-mentioned cosmetic in the form of a hair lotion, hair conditioner, hair rinse, etc. is applied to the hair.
Methods of improving immune function in cancer patients having solid tumors are disclosed. An improvement in immune function can slow or stop tumor growth and can reduce tumor burden. The methods comprise administering an effective amount of a cancer treatment and a non-steroidal Glucocorticoid Receptor Modulator (GRM) or a Selective GRM (SGRM). Cancer treatment may include administration of checkpoint inhibitors. GRM or SGRM administration can induce checkpoint inhibitor sensitivity in cancer. Improvements in immune function may include increased CD8+ T cell activation, increased secretion of pro-inflammatory cytokines, increased TNF α secretion, increased IFN γ secretion, and other changes compared to activation and secretion prior to GRM administration. In embodiments, immune function is improved 1,2,3, or more days after GRM administration. Other patient characteristics may also be improved by the methods disclosed herein. GRM includes heteroaryl-ketone fused azadecalins and octahydro fused azadecalins GRM. GRM administration includes oral GRM administration.
To prepare infusion solutions, dilute 1 mL of alprostadil injection with sodium chloride injection, USP or dextrose injection, USP. Undiluted alprostadil injection may interact with the plastic sidewalls of volumetric infusion chambers causing a change in the appearance of the chamber and creating a hazy solution. Should this occur, the solution and the volumetric infusion chamber should be replaced.

When using a volumetric infusion chamber, the appropriate amount of intravenous infusion solution should be added to the chamber first. The undiluted alprostadil injection should then be added to the intravenous infusion solution, avoiding direct contact of the undiluted solution with the walls of the volumetric infusion chamber.

Dilute to volumes appropriate for the pump delivery system available. Prepare fresh infusion solutions every 24 hours. Discard any solution more than 24 hours old.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin, having high humidity-retaining potency and excellent in safety and stability. SOLUTION: This preparation contains 0.01-30wt.%, preferably 0.1-10wt.% of hydantoin and its derivative of the formula (R1 -R3 are H, a Cn H2n+1 , and phenyl; (n) is 1-10) as an active ingredient. The compound of the formula is a cyclic ureid comprising urea and glycolic acid and improves the keratin water- retaining potency of skin and possesses a similar function to that of urea having an important pharmacological activity such as keratin-softening function in the skin science. Moreover, as the compound of the formula, the same compound containing in molasses is used without or after purification. The compound is also possible to be prepare by treating glycine or aminoacetonitrile with potassium cyanate. By suitably blending a usual component in addition to the compound of the formula, products such as lotions, oils, emulsions, creams and ointments are prepared.
The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and/or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight or prevent weight gain or obesity. In certain embodiments, the weight gain and obesity are associated with administration of anti-psychotic drugs. In an alternative embodiment, the compositions and methods provide berberine or berberine analogs alone or for coadministration with an anti-psychotic agent. In an additional embodiment, the compositions and methods further include a natural product. The usefulness of the present invention is that berberine and berberine analogs do not have synergistic effects with other drugs and administration results in few side effects. Such characteristics of berberine or berberine analogs are a great improvement able to support the widespread use of the compositions and methods of the present invention as therapeutics for the treatment and prevention of weight gain and obesity.
This clinical study adopts a prospective, single-center, single-arm exploratory design. Remote robot-assisted laparoscopic surgery will be performed for gynecological surgical treatment through 5G network, while the safety and effectiveness will be studied.

The research process consists of three stages: the screening phase, the treatment phase and the follow-up phase. The screening phase: On the premise of meeting the inclusion and exclusion criteria, patients who voluntarily participate in robot-assisted surgery are planned to be included. Obtain written informed consent from the subjects, collect clinical data (which may include previous medical examination results), and complete relevant examinations. The treatment phase: The laparoscopic surgical system is combined with 5G network and communication technology for the surgical operation process. The follow-up phase: The physician's observational follow-up of the subjects in the study will continue up to one month post-surgery, and may be extended if necessary. During these three phases, subjects will need to undergo some medical observations or examinations to assess safety and efficacy indicators.
Methods: This is a prospective cohort study which will recruit patients aged over 50 with hip fractures receiving surgical treatment in the Taipei City Hospital. They will be provided home-based PAC, hospital-based PAC, or no formal PAC based on the medical judgment and patients/families' willingness. The period of PAC will be two to three weeks after the acute hospitalization. Assessments include physical function (30 seconds sit to stand, Barthel index, and Harris Hip Score), numerical pain rating scale, EuroQol instrument (EQ-5D), Caregiver Strain Index, and using of medical resources. The assessments will be on the day before discharge from acute hospitalization, and on the discharge day from post-acute care. The follow-up assessment will be at 1, 3, 6, and 12 months after operation. The cost-effectiveness ratio will be defined as the New Taiwan dollars paid for 1-unit improvement of functional performance and quality of life.
* Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.


  * Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

  * Limit dosages and durations to the minimum required.

  * Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).

  * The use of benzodiazepines, including clonazepam orally disintegrating tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing clonazepam orally disintegrating tablets and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).



  * The continued use of benzodiazepines, including clonazepam orally disintegrating tablets, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam orally disintegrating tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam orally disintegrating tablets or reduce the dosage (see DOSAGE AND ADMINISTRATION and WARNINGS).
Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs and transported to NICU on CPAP. After admission to NICU, CPAP will be escalated every 30 minutes up to a maximum level of 7 cm H2O at which point infant would qualify for LISA if the FiO2 requirement is ≥0.3. LISA will be performed using Hobart method. Infants requiring FiO2 \>0.8 to maintain SpO2 88-94% by 20 minutes of life will be intubated in the DR.
After induction of anesthesia, a central venous catheter and a transpulmonary thermodilution catheter (Pulsion Medical Systems, Munich, Germany) are introduced in the right internal jugular vein and in the femoral artery, respectively. The thermodilution catheter is connected to a PiCCO2 monitor (Software version 1.3.0.8). Thereafter, placement of an esophageal doppler probe is performed and the probe is connected to a unique Monitoring System (Deltex Medical, Chichester, UK) with nine different pulse contour algorithms. Cardiac Output by esophageal doppler is used to calibrate the nine different pulse contour algorithms.

After induction of anesthesia and establishment of all monitoring devices, a passive leg raising maneouvre (PLR) is performed and hemodynamic variables including CO by transpulmonary thermodilution (COTPTD) and CO by nine different pulse contour algorithms (COX1-9) are recorded before, during and after PLR. Subsequently, measurements of COTPTD and COX1-9 are carried out every 10 minutes until the beginning of CPB. Fifteen minutes after weaning from cardiopulmonary bypass calibration of nine different pulse contour algorithms by esophageal doppler are performed again and measurements of CITPTD and CIPFX are restarted up to the end of the surgical Intervention.
Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
Familial exudative vitreoretinopathy (FEVR) is a severe genetic disorder characterized by incomplete vascularization of the peripheral retina and associated symptoms that can lead to vision loss. However, the underlying genetic causes of approximately 50% of FEVR cases remain unknown. Here, we report two heterozygous variants in calcyphosine-like gene (CAPSL) that is associated with FEVR. Both variants exhibited compromised CAPSL protein expression. Vascular endothelial cell (EC)-specific inactivation of Capsl resulted in delayed radial/vertical vascular progression, compromised endothelial proliferation/migration, recapitulating the human FEVR phenotypes. CAPSL-depleted human retinal microvascular endothelial cells (HRECs) exhibited impaired tube formation, decreased cell proliferation, disrupted cell polarity establishment, and filopodia/lamellipodia formation, as well as disrupted collective cell migration. Transcriptomic and proteomic profiling revealed that CAPSL abolition inhibited the MYC signaling axis, in which the expression of core MYC targeted genes were profoundly decreased. Furthermore, a combined analysis of CAPSL-depleted HRECs and c-MYC-depleted human umbilical vein endothelial cells uncovered similar transcription patterns. Collectively, this study reports a novel FEVR-associated candidate gene, CAPSL, which provides valuable information for genetic counseling of FEVR. This study also reveals that compromised CAPSL function may cause FEVR through MYC axis, shedding light on the potential involvement of MYC signaling in the pathogenesis of FEVR.